“A great platform to discuss the currently most relevant microbiome topics – a must for microbiome drug developers” PharmaBiome
Microbiome Connect: USA will return to Boston, November 2024.
The program will soon be available to view. Register your interest and be the first to know when our full speaker faculty has been announced!
REGISTER YOUR INTEREST
Features and Networking Events
Agenda
Our conference programme features the latest insights from the industry’s top companies and key thoughts-leaders, tackling the most pertinent issues and trends in the industry.
With three stages of content, you’ll be able to tailor your perfect agenda to meet your specific business needs – allowing you & your team to gain the tangible intel you need to fast-track your product development over the next 12 months.
“A great platform to discuss the currently most relevant microbiome topics – a must for microbiome drug developers” PharmaBiome
Microbiome Connect: USA will return to Boston, November 2024.
The program will soon be available to view. Register your interest and be the first to know when our full speaker faculty has been announced!
REGISTER YOUR INTEREST
Chris McChalicher
Vice President, CMC Technical DevelopmentSeres TherapeuticsKen Blount
VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring CompanyKen Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Terri Young
Executive Vice President, Chief Commercial and Strategy OfficerSeres TherapeuticsTrent Munro
Senior Vice President of TherapeuticsMicroba Life SciencesStaffan Stromberg
Chief Executive OfficerInfant Bacterial TherapeuticsHervé Affagard
Chief Executive OfficerMaaT PharmaDaniel Cuoto
Chief Operating OfficerVedanta BioNikole Kimes
Chief Executive OfficerSiolta TherapeuticsBrice Le François, Ph.D
Senior R&D ManagerDNA GenotekCaroline Mitchell
ProfessorHarvard UniversityAndrew Nealon
Partner and Chief AnalystJoyanceBharat Dixit
Chief Technology OfficerAdiso TherapeuticsPaul Carlson
Principal InvestigatorFDAEllen Turner
Medical OfficerFDA - Center for Biologics Evaluation and Research, Office of Vaccines ResearchBenjamin Hadida
Chief Executive OfficerExeliom BiosciencesHannah Wastyk
Chief Executive OfficerInterface BiosciencesJeffrey Zhao
Chief Executive OfficerNotitia BiotechnologiesSam Possemiers
Chief Executive OfficerMRM HealthTonya Ward
Senior Director, Microbiome Data ScienceRebiotix Inc., a Ferring CompanyPeter Nara
Chief Scientific OfficerKeystone BioDr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.
Julius Goepp
Chief Scientific OfficerEvimeroGabriel Levanthal
Chief Scientific OfficerPharmaBiomeTodd Krueger
President & CEOAOBiomeCassandra Isley
FounderMicrobiome Alliance for Disease PreventionJun Terauchi
Steering Committee ChairJapan Microbiome ConsortiumBecca Senter
Vice President and Head of Preclinical Research and DevelopmentAxial TherapeuticsMary Poor
Vice President of Quality and CMCSiolta TherapeuticsKyongsub Song
Chief Technology OfficerLISCure BiosciencesAlicia Szretter
Director, CMC OperationsVedanta BioRussel Wyborski
Director, VenturesCrohns and Colitis FoundationNicolas Pichon
Head of ManufacturingServatusBob Hettich
ProfessorOak Ridge National LaboratoryCraig Cohen
ProfessorUniversity of California San FranciscoTagbo Niepa
Associate Professor of Chemical EngineeringCarnegie Mellon UniversityAndrea Facciabene
Associate ProfessorUniversity of PennsylvaniaCaleb Bell
Venture PartnerCSBLaurel Lagenaur
Head of ResearchOselNik Sharma
Chief Executive OfficerBioCortexDaniel van der Lelie
Chief Executive OfficerGusto GlobalCarole Schwintner
Chief Technical OfficerMaaT PharmaAkshata Udyavar
Senior Director Immunology and Translational SciencesActymJames Morton
Simons FoundationVivek Lal
Chief Scientific OfficerAlveolus BioCheri Ackerman
CEOConcerto BiosciencesLorenz Rindisbacher
Chief Quality OfficerBactheraNeil Stollman
Chairman, Division of GastroenterologySutter HealthRyan Wilson
Head of LBTSGS-Quay PharmaBernat Olle
CEOVedanta BiosciencesDr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences.
In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.
Amine Zorgani
FounderMicrobiome MavericksFelix Faupel
Chief Commercial OfficerBactheraSonia Timberlake
Former SVP of ResearchFinch TherapeuticsSonia is the Senior Vice President of Research at Finch Therapeutics. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.
Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT.
Jason Ryan
Head of Scientific DevelopmentSacco SystemAnders Gron
Chief Executive OfficerCosmosID, Clinical MicrobiomicsYvonne Nyavor
Principal Scientist, MicrobiomeBoston AnalyticalJeffrey Heiser
Chief Scientific OfficerBoston AnalyticalMelanie Eldridge
Head of Microbiome SciencesArranta Bio / ReciBioPharm
Partnering
Microbiome Connect was founded on connections – on bringing together the breadth of the microbiome ecosystem to make partnerships that will facilitate industry growth. For 2023, we’re bringing a revamped 1-2-1 Partnering Platform allowing all attendees to meet new people, discover new organizations and create incredible new opportunities.
With our Partnering Platform, you’ll have access to efficient networking and collaboration across every use case – from connecting efficiently with new & familiar faces and meeting potential customers & partners, through to raising capital and recruitment.
How can I get involved?
Our Partnering Platform is open to all conference attendees at no additional cost and is the best way to meet everyone you want to meet at Microbiome Connect. To participate, just get your ticket and complete your profile to let other attendees know about you and your organization’s goals. Two days out from the event, you’ll then be able to review hundreds of profiles and select who you want to meet, with the option to filter attendees by therapeutic area, stage of research, and partnering goals. Then, simply join your meetings on-site – it’s as simple as that.
Want to get the most out of the conference?
Take your conference experience to the next level and maximize your ROI through our tailored sponsorship packages. Get in touch with Simon Pickles, Senior Commercial Partnerships Manager, [email protected] to explore how you can meet your company goals at Microbiome Connect.
Pre-Event Workshops
Limited spaces are available for our Pre-Event Workshops, allowing for more in-depth discussion around 2 key themes:
- Women’s Health & the Microbiome
- Streamlining the Regulatory Process to Decrease Time to Market
Networking Zone
Our Networking Zone is the place to be to have partnering meetings, find your next technology, and catch up with your peers over a coffee or lunch. We’ve built more networking time than ever before into the programme this year, giving you plenty of time to catch up with old faces and make the connections you need to fast-track your research.
Gala Drinks Reception
Grab a drink & join us for the return of our Gala Drinks Reception – the perfect way to unwind after a day of presentations and networking.
Women in Microbiome Lunch
Join a community of women who can support each other, share experiences and pave the way for the next generation of leaders in microbiome research. Diversity and inclusion are the keys to unlocking untapped market space, retaining top talent and staying ahead of the competition – and at this lunch, you can connect with fellow female scientists and entrepreneurs as we look to develop a more inclusive & diverse environment in the life sciences industry.
Investor Meet & Greet
Build connections across a series of meeting tables in a casual and interactive environment with investors at your funding stage. Gain advice on common pitfalls when fundraising, what investors look for in potential portfolio companies, and grow to the next stage of your business.
Academics Poster Session
Showcase your academic research to an audience of experts in the space who can guide you as you look to turn your work from a concept to a commercial product. The author of the best poster will receive one hour of mentorship time to help you transition from academia to industry.
Preclinical Programme Showcase
Highlight your promising preclinical program to our jury of industry leading investors and to our wider audience of microbiome specialists. Three programs will be shortlisted by our jury to give a 10-minute presentation at the conference on their hottest preclinical data that’s poised to transform the microbiome therapeutic landscape.
Disease Area-Specific Roundtable Discussions
Take the opportunity to network with pre-registered groups of up to 12 people, where we will be discussing the biggest challenges and opportunities across key disease areas. Each interactive session is 30 minutes, giving you the opportunity to visit two roundtables. Disease Areas to be covered include: Oncology, Gut-Brain Axis, Metabolic Disease, Dermatology, Infectious Disease, Women’s Health, Gastro-Intestinal & Respiratory